NCT05057481

Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus

Reappraisal of Second-line Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Assiut University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

There is a deficiency in guidelines about the treatment of autoimmune hemolytic anemia in systemic lupus erythematosus (SLE), especially in refractory cases. Mycophenolate mofetil (MMF) showed promising results in those patients but still, the data available are in form of case reports. So, investigators will investigate the efficiency of MMF against a well-established treatment Rituximab in the treatment of refractory autoimmune hemolytic anemia in SLE patients.

Detailed description

There is a deficiency in guidelines about the treatment of autoimmune hemolytic anemia in systemic lupus erythematosus (SLE), especially in refractory cases. Mycophenolate mofetil (MMF) showed promising results in those patients but still, the data available are in form of case reports. So, the investigators will investigate the efficiency of MMF against a well-established treatment Rituximab in the treatment of refractory autoimmune hemolytic anemia in SLE patients.

Conditions

• Autoimmune Hemolytic Anemia
• Systemic Lupus Erythematosus

Interventions

Type	Name	Description
DRUG	Mycophenolate Mofetil 500mg	MMF 2gram/day orally for 12 weeks
DRUG	Rituximab	375 mg/m2 of rituximab given intravenously weekly for 4 weeks.

Timeline

• Start date: 2021-09-15
• Primary completion: 2022-12-31
• Completion: 2023-01-15
• First posted: 2021-09-27
• Last updated: 2021-10-27

Locations

1 site across 1 country: Egypt